On June 25, Bio-Techne surges over 19% in intraday trading. The move was triggered by news that Merck KGaA Group has agreed to acquire Bio-Techne at $73 per share in an all-cash transaction.

The acquisition comes after activist investor Ananym Capital Management had sent a letter to Bio-Techne's board urging a strategic review, including a potential sale to a larger industry player. Ananym argued that a sale would deliver more value than Bio-Techne could achieve as a standalone company. The $73 per share offer represents a substantial premium to the analyst consensus price target of $61.42 and the stock's prior trading level near $59.45.

Bio-Techne's attractiveness as an acquisition target was further supported by its strategic positioning in cell therapy through a planned full acquisition of Wilson Wolf, its Ella platform receiving EU CE-IVD certification, and its broad portfolio of life science reagents, instruments, and services serving global research, diagnostics, and bioprocessing markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)